Practical SolutionsEvidence for what works

Mothers dying in childbirth

Maternal healthno solution listed yet

Mothers dying in childbirth: the world is 64% of the way short of its target (SDG 3.1: below 70 per 100,000).

Key messages

  • Size of the gap: 197 deaths per 100,000 births (2023); target 70 (SDG 3.1: below 70 per 100,000).
  • What can be done: no reviewed solution yet; the loop is searching.

Why it is on the list

Indicator SH.STA.MMRT (World Bank): 197 deaths per 100,000 births (2023); target 70 (SDG 3.1: below 70 per 100,000). Gap to target: 64%. Rank 3 of 11. Source data

Solutions

No reviewed solution is listed yet. The loop searches the literature for this problem every cycle; any lead it finds appears below.

Leads found by the loop

Lead, not finding. Everything in this section was found automatically and checked only mechanically. It is a place to look.

Sentences quoted unchanged from systematic-review abstracts and re-checked by a separate step.

Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants at risk of respiratory distress syndrome. (2026) · PubMed 42483935
When all studies are considered, prophylactic surfactant probably results in little to no difference in the risk of chronic lung disease (CLD) at 36 weeks' postmenstrual age compared to selective use of surfactant (RR 1.13, 95% CI 1.00 to 1.28; I² = 0%; RD 0.04, 95% CI 0.00 to 0.08; NNTH 25 95% CI 13 to > 1000; I² = 0%; 5 trials, 1874 infants; moderate-certainty evidence). There may be little to no difference between the prophylactic and selective approaches in moderate to severe neurodevelopmental impairment (RR 0.83, 95% CI 0.57 to 1.21; 1 trial, 976 infants; I 2 not applicable; low-certainty evidence). Studies of prophylactic surfactant administration in infants at risk of developing RDS that were conducted prior to widespread use of maternal prenatal steroids and routine early stabilization on CPAP demonstrated a decreased risk of mortality and slight reduction in pneumothorax compared with selective surfactant use in infants with established RDS. However, larger trials that reflect current neonatal care practices do not support this finding.
every quoted sentence and number found in the abstract
Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. (2026) · PubMed 42689525
Primary outcomes for infants/children: Up to two years' corrected age, magnesium sulphate compared with placebo reduced cerebral palsy (RR 0.71, 95% CI 0.57 to 0.89; 6 RCTs, 6107 children; number needed to treat for additional beneficial outcome (NNTB) 60, 95% CI 41 to 158) and death or cerebral palsy (RR 0.87, 95% CI 0.77 to 0.98; 6 RCTs, 6481 children; NNTB 56, 95% CI 32 to 363) (both high-certainty evidence). Magnesium sulphate probably resulted in little to no difference in death (fetal, neonatal, or later) (RR 0.96, 95% CI 0.82 to 1.13; 6 RCTs, 6759 children); major neurodevelopmental disability (RR 1.09, 95% CI 0.83 to 1.44; 1 RCT, 987 children); or death or major neurodevelopmental disability (RR 0.95, 95% CI 0.85 to 1.07; 3 RCTs, 4279 children) (all moderate-certainty evidence). The currently available evidence indicates that magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus, compared with placebo, reduces cerebral palsy, and death or cerebral palsy, in children up to two years' corrected age. Magnesium sulphate may result in little to no difference in outcomes in children at school age.
every quoted sentence and number found in the abstract

Recent reviews found, not yet reviewed (searched 2026-11-17):

  • Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants at risk of respiratory distress syndrome. (2026) · PubMed
  • Planned early birth versus expectant management for hypertensive disorders from 34 weeks' gestation to term. (2026) · PubMed
  • Home visits following hospital discharge for families with preterm and low-birthweight infants. (2026) · PubMed
  • Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. (2026) · PubMed

Bright spots

Better than income predicts by at least 1.25 standard deviations in both 2022-2026 and 2016-2020. Income is the only control; treat each as a lead to investigate, not a finding.

  • Mozambique: 99 (2023); 2.15 standard deviations better than income predicts now, 1.9 before
  • Syrian Arab Republic: 20 (2023); 1.92 standard deviations better than income predicts now, 1.76 before
  • Tajikistan: 14 (2023); 1.81 standard deviations better than income predicts now, 1.8 before
  • West Bank and Gaza: 16 (2023); 1.94 standard deviations better than income predicts now, 1.43 before
  • Kiribati: 80 (2023); 1.59 standard deviations better than income predicts now, 1.59 before
  • Solomon Islands: 123 (2023); 1.51 standard deviations better than income predicts now, 1.4 before

Open questions

  • No reviewed solution is listed for "Mothers dying in childbirth". Which interventions have randomised or review-level evidence of reducing it?
  • What do Mozambique, Syrian Arab Republic, Tajikistan do differently? They beat their income-predicted level in two periods.

Use and cite this entry

Practical Solutions. "Mothers dying in childbirth". https://tenant-ps-web.ultrastable.workers.dev/problems/maternal. Accessed 2026-11-17.

This entry as JSON · Report an error or suggest a correction